PRLD · Prelude Therapeutics Inc
$4.06
-0.14 (-3.33%)
At close · Jul 20
Market Cap
$323.36M
Shares
79.65M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$12.14M
+73.4%
FY2025
Net Income
-$99.5M
+21.8%
FY2025
Operating Margin
-861.33%
+1134.6pp
FY2025
Diluted EPS
-$1.29
+23.2%
FY2025
Operating Cash Flow
-$56.3M
+45.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | $12.14M | $7M | — | — | — | — | — | |
| $79.09M | $94.3M | $118M | $103.39M | $92.89M | $86.78M | $48.18M | $24.28M | |
| $21.77M | $22.41M | $28.72M | $28.88M | $30.65M | $26.96M | $10.59M | $3.83M | |
| — | $1.71M | $1.77M | $1.17M | $1.32M | $915K | $542K | $382K | |
| — | $1.32M | — | — | — | — | — | — | |
| $100.86M | $116.71M | $146.71M | $132.28M | $123.54M | $113.74M | $58.76M | $28.11M | |
| -$84.14M | -$104.57M | -$139.71M | -$132.28M | -$123.54M | -$113.74M | -$58.76M | -$28.11M | |
| — | -861.33% | -1995.91% | — | — | — | — | — | |
| — | -$102.86M | -$137.94M | -$131.11M | -$122.22M | -$112.82M | -$58.22M | -$27.73M | |
| $6.34M | $5.07M | $12.54M | $10.45M | $8.1M | $2.04M | $1.83M | $539K | |
| — | $0 | $0 | — | — | — | — | — | |
| -$77.8M | -$99.5M | -$127.17M | -$121.83M | -$115.44M | -$111.69M | -$56.93M | -$27.57M | |
| — | -819.59% | -1816.76% | — | — | — | — | — | |
| -$77.85M | -$99.53M | -$127.36M | -$119.92M | -$116.42M | -$112.41M | -$56.93M | — | |
| USD/shares | — | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | — | — |
| USD/shares | — | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | — | — |
| shares | — | 76.96M | 75.81M | 60.36M | 47.37M | 46.05M | 12.48M | 1.67M |
| shares | — | 76.96M | 75.81M | 60.36M | 47.37M | 46.05M | 12.48M | 1.67M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.20×
P/E (TTM)
—
Biotechnology median 7.03×